Synergy Pharmaceuticals Inc. (SGYP) Is At $2.22 Formed Wedge; Benchmark Electronics, Inc. (BHE) Covered By 2 Bulls

Synergy Pharmaceuticals Inc. (SGYP) formed wedge down with $2.15 target or 3.00% below today’s $2.22 share price. Synergy Pharmaceuticals Inc. (SGYP) has $547.59 million valuation. The stock increased 1.83% or $0.04 during the last trading session, reaching $2.22. About 5.53M shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since January 9, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.

Among 5 analysts covering Benchmark Electronics (NYSE:BHE), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Benchmark Electronics had 17 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, July 18 by Needham. The stock has “Sell” rating by Cross Research on Friday, October 21. The stock of Benchmark Electronics, Inc. (NYSE:BHE) earned “Buy” rating by Needham on Friday, July 22. The rating was maintained by Needham with “Buy” on Wednesday, August 30. On Thursday, October 12 the stock rating was maintained by RBC Capital Markets with “Hold”. Needham maintained it with “Buy” rating and $34 target in Thursday, February 9 report. The firm earned “Outperform” rating on Friday, July 24 by Raymond James. Needham maintained the shares of BHE in report on Friday, October 23 with “Buy” rating. RBC Capital Markets maintained the shares of BHE in report on Friday, October 23 with “Sector Perform” rating. The stock of Benchmark Electronics, Inc. (NYSE:BHE) has “Buy” rating given on Friday, May 27 by Berenberg. See Benchmark Electronics, Inc. (NYSE:BHE) latest ratings:

19/10/2017 Broker: Needham Rating: Hold Downgrade
12/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $37.0 Maintain
31/08/2017 Broker: RBC Capital Markets Rating: Hold New Target: $37.0 Maintain
30/08/2017 Broker: Needham Rating: Buy New Target: $37.0 Maintain
20/07/2017 Broker: RBC Capital Markets Rating: Hold New Target: $37.0000
18/07/2017 Broker: Needham Rating: Buy Old Target: $34 New Target: $37 Maintain

Since August 7, 2017, it had 0 insider buys, and 1 insider sale for $98,972 activity. PAULSON & CO. INC. also sold $98,972 worth of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Monday, August 7.

Analysts await Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) to report earnings on March, 7. They expect $-0.20 earnings per share, up 35.48% or $0.11 from last year’s $-0.31 per share. After $-0.22 actual earnings per share reported by Synergy Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -9.09% EPS growth.

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals had 35 analyst reports since August 25, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 9 by Cantor Fitzgerald. As per Thursday, October 1, the company rating was initiated by H.C. Wainwright. The rating was reinitiated by TH Capital with “Buy” on Thursday, October 29. The firm has “Buy” rating by H.C. Wainwright given on Monday, December 4. The rating was maintained by Rodman & Renshaw on Friday, December 23 with “Buy”. On Wednesday, June 7 the stock rating was maintained by Cantor Fitzgerald with “Buy”. On Friday, January 20 the stock rating was maintained by Rodman & Renshaw with “Buy”. The firm earned “Buy” rating on Monday, January 8 by H.C. Wainwright. The rating was maintained by Cantor Fitzgerald on Thursday, November 9 with “Buy”. The rating was downgraded by Citigroup on Thursday, April 6 to “Sell”.

Investors sentiment increased to 1.9 in 2017 Q3. Its up 0.41, from 1.49 in 2017Q2. It is positive, as 16 investors sold Synergy Pharmaceuticals Inc. shares while 23 reduced holdings. 21 funds opened positions while 53 raised stakes. 147.06 million shares or 7.33% less from 158.68 million shares in 2017Q2 were reported. Orbimed Advisors Lc reported 0.38% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Valley National Advisers accumulated 4,000 shares. State Bank Of Mellon owns 1.17M shares. Family Mgmt invested in 80,500 shares. Kingdon has 769,140 shares. Prelude Capital Mngmt Ltd Liability Company has 0.04% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 139,704 shares. Ubs Asset Americas invested 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Virtu Fincl Ltd Liability Com holds 28,936 shares or 0% of its portfolio. National Bank Of America De reported 88,245 shares. First Republic Invest Mgmt has invested 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Tiaa Cref Limited Com has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Lehman Fin Res holds 0.02% or 13,500 shares. Moreover, Palisade Cap Mngmt Limited Liability Nj has 0.01% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 80,674 shares. California State Teachers Retirement Sys stated it has 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Hikari holds 0.56% or 1.50 million shares.

The stock increased 0.50% or $0.15 during the last trading session, reaching $30.1. About 308,984 shares traded. Benchmark Electronics, Inc. (NYSE:BHE) has risen 60.40% since January 9, 2017 and is uptrending. It has outperformed by 43.70% the S&P500.

Since August 17, 2017, it had 0 insider buys, and 2 selling transactions for $221,032 activity. PETERSON SCOTT R sold $32,063 worth of Benchmark Electronics, Inc. (NYSE:BHE) on Thursday, September 7. DUNCAN DOUGLAS G sold 5,922 shares worth $188,969.

Benchmark Electronics, Inc., together with its subsidiaries, provides integrated electronic manufacturing services in the Americas, Asia, and Europe. The company has market cap of $1.50 billion. The firm offers engineering services and solutions, including solution development, concept, and design services; new product design, prototype, testing, and related engineering services; and custom testing, and automation equipment design and build services. It has a 23.91 P/E ratio. It also provides electronics manufacturing and testing services, such as printed circuit board assembly and test solutions, assembly of subsystems, circuitry and functionality testing of printed assemblies, environmental and stress testing, and component reliability testing; component engineering services; manufacturing defect analysis, in-circuit testing, functional testing, flexible test solutions, environmental stress tests of assemblies of boards or systems; and failure analysis.